CD274 and non-small cell lung carcinoma: There are opinions in favor of the GPS being superior to the ECOG‐PS in predicting the prognosis of patients with NSCLC and high PD‐L1 expression who receive first‐line pembrolizumab monotherapy; however, the GPS and ECOG‐PS alone are significantly associated.